Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens.

MLA

Zheng, Yu, et al. “Antiretroviral Therapy and Efficacy After Virologic Failure on First-Line Boosted Protease Inhibitor Regimens.” Clinical Infectious Diseases, vol. 59, no. 6, Sept. 2014, pp. 888–96. EBSCOhost, https://doi.org/10.1093/cid/ciu367.

APA

Zheng, Y., Hughes, M. D., Lockman, S., Benson, C. A., Hosseinipour, M. C., Campbell, T. B., Gulick, R. M., Daar, E. S., Sax, P. E., Riddler, S. A., Haubrich, R., Salata, R. A., & Currier, J. S. (2014). Antiretroviral Therapy and Efficacy After Virologic Failure on First-line Boosted Protease Inhibitor Regimens. Clinical Infectious Diseases, 59(6), 888–896. https://doi.org/10.1093/cid/ciu367

Chicago

Zheng, Yu, Michael D. Hughes, Shahin Lockman, Constance A. Benson, Mina C. Hosseinipour, Thomas B. Campbell, Roy M. Gulick, et al. 2014. “Antiretroviral Therapy and Efficacy After Virologic Failure on First-Line Boosted Protease Inhibitor Regimens.” Clinical Infectious Diseases 59 (6): 888–96. doi:10.1093/cid/ciu367.